Global Metastatic Ovarian Cancer Drug Market Research Report 2019

Table of Contents

Executive Summary

1 Metastatic Ovarian Cancer Drug Market Overview

• 1.1 Product Overview and Scope of Metastatic Ovarian Cancer Drug
• 1.2 Metastatic Ovarian Cancer Drug Segment by Type
  • 1.2.1 Global Metastatic Ovarian Cancer Drug Production Growth Rate Comparison by Type (2014-2025)
  • 1.2.2 E-7449
  • 1.2.3 Crizotinib
  • 1.2.4 CMB-305
  • 1.2.5 G-305
  • 1.2.6 LV-305
  • 1.2.7 Others
• 1.3 Metastatic Ovarian Cancer Drug Segment by Application
  • 1.3.1 Metastatic Ovarian Cancer Drug Consumption Comparison by Application (2014-2025)
  • 1.3.2 Clinic
  • 1.3.3 Hospital
  • 1.3.4 Others
• 1.3 Global Metastatic Ovarian Cancer Drug Market by Region
  • 1.3.1 Global Metastatic Ovarian Cancer Drug Market Size Region
  • 1.3.2 North America Status and Prospect (2014-2025)
  • 1.3.3 Europe Status and Prospect (2014-2025)
  • 1.3.4 China Status and Prospect (2014-2025)
  • 1.3.5 Japan Status and Prospect (2014-2025)
  • 1.3.6 Southeast Asia Status and Prospect (2014-2025)
  • 1.3.7 India Status and Prospect (2014-2025)
• 1.4 Global Metastatic Ovarian Cancer Drug Market Size
  • 1.4.1 Global Metastatic Ovarian Cancer Drug Revenue (2014-2025)
  • 1.4.2 Global Metastatic Ovarian Cancer Drug Production (2014-2025)

2 Global Metastatic Ovarian Cancer Drug Market Competition by Manufacturers

• 2.1 Global Metastatic Ovarian Cancer Drug Production Market Share by Manufacturers (2014-2019)
• 2.2 Global Metastatic Ovarian Cancer Drug Revenue Share by Manufacturers (2014-2019)
• 2.3 Global Metastatic Ovarian Cancer Drug Average Price by Manufacturers (2014-2019)
• 2.4 Manufacturers Metastatic Ovarian Cancer Drug Production Sites, Area Served, Product Types
• 2.5 Metastatic Ovarian Cancer Drug Market Competitive Situation and Trends
  • 2.5.1 Metastatic Ovarian Cancer Drug Market Concentration Rate
  • 2.5.2 Metastatic Ovarian Cancer Drug Market Share of Top 3 and Top 5 Manufacturers
  • 2.5.3 Mergers & Acquisitions, Expansion

3 Global Metastatic Ovarian Cancer Drug Production Market Share by Regions

• 3.1 Global Metastatic Ovarian Cancer Drug Production Market Share by Regions
• 3.2 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Regions (2014-2019)
• 3.3 Global Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
• 3.4 North America Metastatic Ovarian Cancer Drug Production
  • 3.4.1 North America Metastatic Ovarian Cancer Drug Production Growth Rate (2014-2019)
  • 3.4.2 North America Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
• 3.5 Europe Metastatic Ovarian Cancer Drug Production
  • 3.5.1 Europe Metastatic Ovarian Cancer Drug Production Growth Rate (2014-2019)
  • 3.5.2 Europe Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
• 3.6 China Metastatic Ovarian Cancer Drug Production (2014-2019)
  • 3.6.1 China Metastatic Ovarian Cancer Drug Production Growth Rate (2014-2019)
  • 3.6.2 China Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
• 3.7 Japan Metastatic Ovarian Cancer Drug Production (2014-2019)
  • 3.7.1 Japan Metastatic Ovarian Cancer Drug Production Growth Rate (2014-2019)
  • 3.7.2 Japan Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)

4 Global Metastatic Ovarian Cancer Drug Consumption by Regions

• 4.1 Global Metastatic Ovarian Cancer Drug Consumption by Regions
• 4.2 North America Metastatic Ovarian Cancer Drug Consumption (2014-2019)
• 4.3 Europe Metastatic Ovarian Cancer Drug Consumption (2014-2019)
• 4.4 China Metastatic Ovarian Cancer Drug Consumption (2014-2019)
• 4.5 Japan Metastatic Ovarian Cancer Drug Consumption (2014-2019)

5 Global Metastatic Ovarian Cancer Drug Production, Revenue, Price Trend by Type

• 5.1 Global Metastatic Ovarian Cancer Drug Production Market Share by Type (2014-2019)
• 5.2 Global Metastatic Ovarian Cancer Drug Revenue Market Share by Type (2014-2019)
• 5.3 Global Metastatic Ovarian Cancer Drug Price by Type (2014-2019)
• 5.4 Global Metastatic Ovarian Cancer Drug Production Growth by Type (2014-2019)

6 Global Metastatic Ovarian Cancer Drug Market Analysis by Applications

• 6.1 Global Metastatic Ovarian Cancer Drug Consumption Market Share by Application (2014-2019)
• 6.2 Global Metastatic Ovarian Cancer Drug Consumption Growth Rate by Application (2014-2019)

7 Company Profiles and Key Figures in Metastatic Ovarian Cancer Drug Business

• 7.1 Adgero Biopharmaceuticals Inc
  • 7.1.1 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Production Sites and Area Served
  • 7.1.2 Metastatic Ovarian Cancer Drug Product Introduction, Application and Specification
  • 7.1.3 Adgero Biopharmaceuticals Inc Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.1.4 Main Business and Markets Served
• 7.2 Cellceutix Corporation
  • 7.2.1 Cellceutix Corporation Metastatic Ovarian Cancer Drug Production Sites and Area Served
  • 7.2.2 Metastatic Ovarian Cancer Drug Product Introduction, Application and Specification
  • 7.2.3 Cellceutix Corporation Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.2.4 Main Business and Markets Served
• 7.3 Eisai Co., Ltd.
  • 7.3.1 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Production Sites and Area Served
  • 7.3.2 Metastatic Ovarian Cancer Drug Product Introduction, Application and Specification
  • 7.3.3 Eisai Co., Ltd. Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.3.4 Main Business and Markets Served
• 7.4 F. Hoffmann-La Roche Ltd.
  • 7.4.1 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Production Sites and Area Served
  • 7.4.2 Metastatic Ovarian Cancer Drug Product Introduction, Application and Specification
  • 7.4.3 F. Hoffmann-La Roche Ltd. Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.4.4 Main Business and Markets Served
• 7.5 Immune Design Corp.
  • 7.5.1 Immune Design Corp. Metastatic Ovarian Cancer Drug Production Sites and Area Served
  • 7.5.2 Metastatic Ovarian Cancer Drug Product Introduction, Application and Specification
  • 7.5.3 Immune Design Corp. Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.5.4 Main Business and Markets Served
• 7.6 Millennium Pharmaceuticals Inc
  • 7.6.1 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Production Sites and Area Served
  • 7.6.2 Metastatic Ovarian Cancer Drug Product Introduction, Application and Specification
  • 7.6.3 Millennium Pharmaceuticals Inc Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.6.4 Main Business and Markets Served
• 7.7 MolMed S.p.A.
  • 7.7.1 MolMed S.p.A. Metastatic Ovarian Cancer Drug Production Sites and Area Served
  • 7.7.2 Metastatic Ovarian Cancer Drug Product Introduction, Application and Specification
  • 7.7.3 MolMed S.p.A. Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.7.4 Main Business and Markets Served
• 7.8 Natco Pharma Limited
  • 7.8.1 Natco Pharma Limited Metastatic Ovarian Cancer Drug Production Sites and Area Served
  • 7.8.2 Metastatic Ovarian Cancer Drug Product Introduction, Application and Specification
  • 7.8.3 Natco Pharma Limited Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.8.4 Main Business and Markets Served
• 7.9 Northwest Biotherapeutics, Inc.
  • 7.9.1 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Production Sites and Area Served
  • 7.9.2 Metastatic Ovarian Cancer Drug Product Introduction, Application and Specification
  • 7.9.3 Northwest Biotherapeutics, Inc. Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.9.4 Main Business and Markets Served
• 7.10 Pfizer Inc.
  • 7.10.1 Pfizer Inc. Metastatic Ovarian Cancer Drug Production Sites and Area Served
  • 7.10.2 Metastatic Ovarian Cancer Drug Product Introduction, Application and Specification
  • 7.10.3 Pfizer Inc. Metastatic Ovarian Cancer Drug Production, Revenue, Price and Gross Margin (2014-2019)
  • 7.10.4 Main Business and Markets Served
• 7.11 Richter Gedeon Nyrt.
• 7.12 Sumitomo Dainippon Pharma Co., Ltd.
• 7.13 VG Life Sciences, Inc.

8 Metastatic Ovarian Cancer Drug Manufacturing Cost Analysis

• 8.1 Metastatic Ovarian Cancer Drug Key Raw Materials Analysis
  • 8.1.1 Key Raw Materials
  • 8.1.2 Price Trend of Key Raw Materials
  • 8.1.3 Key Suppliers of Raw Materials
• 8.2 Proportion of Manufacturing Cost Structure
• 8.3 Manufacturing Process Analysis of Metastatic Ovarian Cancer Drug
• 8.4 Metastatic Ovarian Cancer Drug Industrial Chain Analysis

9 Marketing Channel, Distributors and Customers

• 9.1 Marketing Channel
  • 9.1.1 Direct Marketing
  • 9.1.2 Indirect Marketing
• 9.2 Metastatic Ovarian Cancer Drug Distributors List
• 9.3 Metastatic Ovarian Cancer Drug Customers

10 Market Dynamics

• 10.1 Market Trends
• 10.2 Opportunities
• 10.3 Market Drivers
• 10.4 Challenges
• 10.5 Influence Factors

11 Global Metastatic Ovarian Cancer Drug Market Forecast

• 11.1 Global Metastatic Ovarian Cancer Drug Production, Revenue Forecast
  • 11.1.1 Global Metastatic Ovarian Cancer Drug Production Growth Rate Forecast (2019-2025)
  • 11.1.2 Global Metastatic Ovarian Cancer Drug Revenue and Growth Rate Forecast (2019-2025)
  • 11.1.3 Global Metastatic Ovarian Cancer Drug Price and Trend Forecast (2019-2025)
• 11.2 Global Metastatic Ovarian Cancer Drug Production Forecast by Regions (2019-2025)
  • 11.2.1 North America Metastatic Ovarian Cancer Drug Production, Revenue Forecast (2019-2025)
  • 11.2.2 Europe Metastatic Ovarian Cancer Drug Production, Revenue Forecast (2019-2025)
  • 11.2.3 China Metastatic Ovarian Cancer Drug Production, Revenue Forecast (2019-2025)
  • 11.2.4 Japan Metastatic Ovarian Cancer Drug Production, Revenue Forecast (2019-2025)
• 11.3 Global Metastatic Ovarian Cancer Drug Consumption Forecast by Regions (2019-2025)
  • 11.3.1 North America Metastatic Ovarian Cancer Drug Consumption Forecast (2019-2025)
  • 11.3.2 Europe Metastatic Ovarian Cancer Drug Consumption Forecast (2019-2025)
  • 11.3.3 China Metastatic Ovarian Cancer Drug Consumption Forecast (2019-2025)
  • 11.3.4 Japan Metastatic Ovarian Cancer Drug Consumption Forecast (2019-2025)
• 11.4 Global Metastatic Ovarian Cancer Drug Production, Revenue and Price Forecast by Type (2019-2025)
• 11.5 Global Metastatic Ovarian Cancer Drug Consumption Forecast by Application (2019-2025)

12 Research Findings and Conclusion

13 Methodology and Data Source

• 13.1 Methodology/Research Approach
  • 13.1.1 Research Programs/Design
  • 13.1.2 Market Size Estimation
  • 13.1.3 Market Breakdown and Data Triangulation
• 13.2 Data Source
  • 13.2.1 Secondary Sources
  • 13.2.2 Primary Sources
• 13.3 Author List